Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May 5;6(5):e1000061.
doi: 10.1371/journal.pmed.1000061. Epub 2009 May 12.

Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study

Affiliations

Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study

Radek Bukowski et al. PLoS Med. .

Abstract

Background: Low plasma folate concentrations in pregnancy are associated with preterm birth. Here we show an association between preconceptional folate supplementation and the risk of spontaneous preterm birth.

Methods and findings: In a cohort of 34,480 low-risk singleton pregnancies enrolled in a study of aneuploidy risk, preconceptional folate supplementation was prospectively recorded in the first trimester of pregnancy. Duration of pregnancy was estimated based on first trimester ultrasound examination. Natural length of pregnancy was defined as gestational age at delivery in pregnancies with no medical or obstetrical complications that may have constituted an indication for delivery. Spontaneous preterm birth was defined as duration of pregnancy between 20 and 37 wk without those complications. The association between preconceptional folate supplementation and the risk of spontaneous preterm birth was evaluated using survival analysis. Comparing to no supplementation, preconceptional folate supplementation for 1 y or longer was associated with a 70% decrease in the risk of spontaneous preterm delivery between 20 and 28 wk (41 [0.27%] versus 4 [0.04%] spontaneous preterm births, respectively; HR 0.22, 95% confidence interval [CI] 0.08-0.61, p = 0.004) and a 50% decrease in the risk of spontaneous preterm delivery between 28 and 32 wk (58 [0.38%] versus 12 [0.18%] preterm birth, respectively; HR 0.45, 95% CI 0.24-0.83, p = 0.010). Adjustment for maternal characteristics age, race, body mass index, education, marital status, smoking, parity, and history of prior preterm birth did not have a material effect on the association between folate supplementation for 1 y or longer and spontaneous preterm birth between 20 and 28, and 28 to 32 wk (adjusted HR 0.31, 95% CI 0.11-0.90, p = 0.031 and 0.53, 0.28-0.99, p = 0.046, respectively). Preconceptional folate supplementation was not significantly associated with the risk of spontaneous preterm birth beyond 32 wk. The association between shorter duration (<1 y) of preconceptional folate supplementation and the risk of spontaneous preterm birth was not significant after adjustment for maternal characteristics. However, the risk of spontaneous preterm birth decreased with the duration of preconceptional folate supplementation (test for trend of survivor functions, p = 0.01) and was the lowest in women who used folate supplementation for 1 y or longer. There was also no significant association with other complications of pregnancy studied after adjustment for maternal characteristics.

Conclusions: Preconceptional folate supplementation is associated with a 50%-70% reduction in the incidence of early spontaneous preterm birth. The risk of early spontaneous preterm birth is inversely proportional to the duration of preconceptional folate supplementation. Preconceptional folate supplementation was specifically related to early spontaneous preterm birth and not associated with other complications of pregnancy.

PubMed Disclaimer

Conflict of interest statement

Mary D'Alton has acted as a consultant for Artemis Health.

Figures

Figure 1
Figure 1. Cumulative risk of spontaneous preterm birth in relation to duration of preconceptional folate supplementation.
Folate = 0*, no preconceptional folate supplementation; Folate <1 yr*, preconceptional folate supplementation for less than a year; Folate > = 1 yr*, preconceptional folate supplementation for a year or longer. *Test for trend of survivor functions, p = 0.01.
Figure 2
Figure 2. Risk of spontaneous preterm birth before 32 wk in relation to duration of preconceptional folate supplementation.
Proportion (mean ± standard error) of spontaneous preterm births before 32 wk in women with no preconceptional folate supplementation and supplementation for <1, 1–2, 3–4, 5–6, 7–11, and >12 mo.
Figure 3
Figure 3. Relative risk of spontaneous preterm birth in relation to duration of preconceptional folate supplementation.
HRs and 95% CIs for spontaneous preterm birth in women with preconceptional folate supplementation for a year or longer (•) or less than a year (▪), compared to women without preconceptional folate supplementation – reference value (○), from Cox proportional hazard regression. *Wald test for equality of hazard ratios, testing the joint hypothesis that coefficients are equal to 0 and that they are equal to each other . SPTB, spontaneous preterm birth.
Figure 4
Figure 4. Stratified analysis of association between preconceptional folate supplementation ≥1 y and the risk of spontaneous preterm birth before 32 wk.
ORs and 95% CIs of spontaneous preterm birth before 32 wk for preconceptional folate supplementation for ≥1 y, stratified for a given characteristic and adjusted for all other maternal characteristics. p-Values are estimated for interaction terms between duration of folate supplementation and given characteristic. The OR for BMI <18.5 could not be estimated, as there were no cases of spontaneous preterm birth before 32 wk among women using folate supplementation for ≥1 y and with BMI <18.5. MA, maternal age; Educ, completed years of education; PARA No PPTB, parous woman without a history of prior preterm birth; PARA PPTB, parous woman with a history of prior preterm birth.

Comment in

Similar articles

Cited by

References

    1. Institute of Medicine. Preterm birth: causes, consequences, and prevention. Washington, DC: National Academy of Sciences; 2007.
    1. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379–2385. - PubMed
    1. Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev. 2006;CD004947 - PubMed
    1. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005;105:267–272. - PubMed
    1. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462–469. - PubMed

Publication types